| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, Boc‑β‑HoAsp(OBzl)‑OH does not possess a specific pharmacological target. Its role is to serve as a protected building block for the introduction of a β‑homoisoaspartic acid moiety into peptide chains. The β‑amino acid framework can significantly alter the conformational preferences of peptides, making them more rigid and resistant to enzymatic degradation, which is valuable in drug discovery. The compound itself does not interact with biological receptors or enzymes; its “target” is the peptide bond formation during chemical synthesis. The orthogonal protecting groups (Boc and OBzl) allow for selective deprotection and further derivatization, enabling the construction of complex peptide architectures. In medicinal chemistry, such building blocks are used to improve the pharmacokinetic and pharmacodynamic properties of peptide‑based therapeutics, but the free amino acid derivative is not intended for direct biological activity.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Boc‑β‑HoAsp(OBzl)‑OH is evaluated solely through its performance in peptide synthesis, not through biological assays. In standard Boc‑SPPS, the compound (typically 3‑5 equivalents) is coupled to a resin‑bound amine using reagents such as DIC/HOBt or HATU in the presence of DIEA, at room temperature for 1‑4 hours. Coupling efficiency is monitored by the Kaiser test or HPLC, and yields routinely exceed 95% when optimized conditions are used. Purity is assessed by analytical HPLC (≥98%) and identity is confirmed by ¹H‑NMR and high‑resolution mass spectrometry. The compound does not exhibit any inherent enzyme inhibition or receptor binding because its functional groups are masked by protective groups and its structure is not designed for biological interactions. Its in vitro utility is strictly confined to chemical synthesis as a precursor for more complex β‑peptide sequences that may later be tested for bioactivity. |
| ln Vivo |
In vivo activity is not applicable for Boc‑β‑HoAsp(OBzl)‑OH, as this compound is not intended for administration to living organisms. It is exclusively a research chemical and synthetic intermediate used in laboratory settings for peptide preparation. The compound is not formulated for any route of administration, and no animal efficacy or safety studies have been conducted with the protected amino acid. Any biological effects would only be relevant after the protecting groups are removed and the resulting β‑homoisoaspartic acid is incorporated into a peptide that is subsequently tested in vivo; however, such studies are performed on the final peptide, not on the building block itself. Its utility lies entirely in the chemical synthesis domain, and it is stored and handled under standard laboratory conditions without consideration for pharmacokinetic or pharmacodynamic properties.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non‑cellular) experimental workflow for Boc‑β‑HoAsp(OBzl)‑OH is based on standard peptide synthesis and characterization procedures, not on binding assays. Typically, the compound (1.0 equivalent) is dissolved in anhydrous DMF or DCM, and a coupling reagent (e.g., HATU, 1.1 equiv.) and a base (e.g., DIEA, 2 equiv.) are added, followed by the amine component (e.g., resin‑bound peptide or a free amino ester). The reaction mixture is stirred at room temperature for 1‑4 hours, and progress is monitored by TLC. After completion, the product is isolated by filtration (for SPPS) or by extraction and purified by flash chromatography (for solution‑phase). Characterization includes ¹H‑NMR, ¹³C‑NMR, and mass spectrometry to confirm structure and purity. Chiral HPLC or polarimetry may be used to verify enantiomeric integrity. The benzyl ester can be selectively removed by hydrogenation (H₂/Pd‑C) to reveal the free side‑chain carboxylate for further modification.
|
| Cell Assay |
In vitro cell‑based experimental workflows are not performed with Boc‑β‑HoAsp(OBzl)‑OH, as it is not intended for direct biological activity screening. However, when used as a building block in peptide synthesis, the final deprotected peptide containing the β‑homoisoaspartic acid residue may be subjected to cell‑based assays. In such cases, the protected amino acid itself is not used; instead, the purified peptide is applied to relevant cell lines (e.g., cancer cells, endothelial cells, or neurons) at concentrations typically ranging from 0.1 to 100 µM for 24‑72 hours. Assays may include cell viability (MTT), apoptosis (Annexin V), or functional readouts such as calcium flux or reporter gene activation. The protective groups on the building block would interfere with cellular uptake and target engagement, so they are always removed before testing.
|
| Animal Protocol |
In vivo animal experimental workflows are not applicable for Boc‑β‑HoAsp(OBzl)‑OH because it is exclusively a synthetic intermediate, not a drug candidate. There are no established animal models or in vivo protocols associated with the protected amino acid. Any in vivo studies would involve the final deprotected peptide products that incorporate the β‑homoaspartic acid residue, rather than the building block itself. The compound is stored under standard conditions (e.g., ‑20°C) and handled in a fume hood with appropriate personal protective equipment. No animal handling or dosing protocols exist for this compound, and it is not used in veterinary or preclinical research as a standalone agent.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Boc‑β‑HoAsp(OBzl)‑OH have not been characterized, as the compound is not intended for pharmaceutical use. Being a protected amino acid with a molecular weight of 323.34 g/mol and a predicted LogP of approximately 2.5, it would be expected to have moderate lipophilicity if administered. However, the compound is never administered to living systems, and any pharmacokinetic data would pertain to the deprotected peptide products rather than the building block. The compound is stable under recommended storage conditions (powder at ‑20°C for up to 3 years) and is not designed for systemic exposure. No ADME (absorption, distribution, metabolism, excretion) studies have been conducted for this compound, as it is used solely as a chemical reagent.
|
| Toxicity/Toxicokinetics |
Toxicological data for Boc‑β‑HoAsp(OBzl)‑OH are limited because it is not a pharmaceutical agent. Standard safety precautions apply: it may cause skin and eye irritation, and inhalation of dust should be avoided. The compound should be handled in a fume hood with appropriate personal protective equipment, including gloves, safety glasses, and a laboratory coat. No chronic toxicity, carcinogenicity, or reproductive toxicity studies have been conducted, as these are not relevant for a synthetic intermediate. The compound is intended for research use only and is not approved for human or veterinary applications. It is not classified as a hazardous substance under most regulatory frameworks, but standard laboratory chemical safety practices should be followed at all times.
|
| References | |
| Additional Infomation |
Boc‑β‑HoAsp(OBzl)‑OH is a specialized reagent in peptide chemistry, widely used for the synthesis of β‑peptides and peptidomimetics. The incorporation of β‑amino acids can confer enhanced metabolic stability and defined conformational properties, making this building block valuable for structure‑based drug design. It is commercially available from multiple suppliers with purity ≥98% and is employed in both academic and industrial research for developing enzyme inhibitors, receptor agonists/antagonists, and antimicrobial peptides. The compound is not a drug and has not undergone clinical trials or received regulatory approval. Its primary applications include the synthesis of constrained cyclic peptides, the study of β‑turn motifs, and the development of proteolytically stable therapeutic candidates. The compound is for research use only and is not intended for diagnostic or therapeutic purposes.
|
| Molecular Formula |
C17H23NO6
|
|---|---|
| Molecular Weight |
337.37
|
| Exact Mass |
337.153
|
| CAS # |
254101-10-5
|
| PubChem CID |
2761513
|
| Appearance |
White to off-white solid powder
|
| Density |
1.197g/cm3
|
| Boiling Point |
522.6ºC at 760mmHg
|
| Flash Point |
269.9ºC
|
| Vapour Pressure |
9.49E-12mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
2.878
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
24
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C(N([H])[C@]([H])(C([H])([H])C(=O)O[H])C([H])([H])C(=O)OC([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
FAFJSSKTLCNWRJ-CYBMUJFWSA-N
|
| InChi Code |
InChI=1S/C17H23NO6/c1-17(2,3)24-16(22)18-13(9-14(19)20)10-15(21)23-11-12-7-5-4-6-8-12/h4-8,13H,9-11H2,1-3H3,(H,18,22)(H,19,20)/t13-/m1/s1
|
| Chemical Name |
(3R)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-phenylmethoxypentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (296.41 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9641 mL | 14.8205 mL | 29.6410 mL | |
| 5 mM | 0.5928 mL | 2.9641 mL | 5.9282 mL | |
| 10 mM | 0.2964 mL | 1.4821 mL | 2.9641 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
